Fiche société
Amgen
Traitements, essais et publications liés.
Traitements26programmes
Essais15liés
Publications9liées
SourceDBlocale
Traitements
26| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AMG334The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments. | Migraine | Phase 4 | À vérifier | United States, Argentina, Austria, Belgium, Czechia, Finland, France, Germany, … | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | United States, Bulgaria, Czechia, Hungary, Italy, Poland, Portugal, Romania, … | À vérifier |
| Erenumab Dose 1This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Colombia, Poland | À vérifier |
| Erenumab Dose 2This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Colombia, Poland | À vérifier |
| Erenumab Dose 3This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Colombia, Poland | À vérifier |
| EvolocumabThe primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]). | Maladie coronarienne | Phase 4 | À vérifier | United States, Brazil, Sweden | À vérifier |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Lupus, Myasthénie | Phase 2 | À vérifier | United States, Argentina, Brazil, France, Italy, Poland, Spain, United Kingdom | À vérifier |
| Maridebart cafraglutideThis trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred. | Insuffisance cardiaque | Phase 3 | Traitement symptomatique | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, … | À vérifier |
| Oral ProphylacticThe purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments. | Migraine | Phase 4 | À vérifier | United States, Argentina, Austria, Belgium, Czechia, Finland, France, Germany, … | À vérifier |
| Routine Lipid ManagementThe primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]). | Maladie coronarienne | Phase 4 | À vérifier | United States, Brazil, Sweden | À vérifier |
| SotorasibThe primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, … | À vérifier |
| Erenumab Dose 1This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Colombia, Poland | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | United States, Bulgaria, Czechia, Hungary, Italy, Poland, Portugal, Romania, Spain | À vérifier |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Lupus | Phase 2 | United States, Australia, Belgium, France, Germany, Italy, Portugal, Spain, United Arab Emirates, United Kingdom | À vérifier | |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Myasthénie | Phase 2 | À vérifier | United States, Argentina, Brazil, France, Italy, Poland, Spain, United Kingdom | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | À vérifier | Traitement symptomatique | Austria | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | Germany | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | United States | À vérifier |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Myasthénie | Phase 3 | À vérifier | United States, Argentina, Belarus, Brazil, Canada, China, Denmark, France, Germany, India, Italy, Japan, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine | À vérifier |
| Erenumab Dose 1This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, Japan, Poland, Puerto Rico, Russia, United Kingdom | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | Denmark, Iceland | À vérifier |
| AMG334The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments. | Migraine | Phase 4 | À vérifier | United States, Argentina, Austria, Belgium, Czechia, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Poland, Portugal, Slovakia, Spain, United Kingdom | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | À vérifier | Traitement symptomatique | Austria | À vérifier |
| SotorasibThe primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, … | À vérifier |
| Maridebart cafraglutideThis trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred. | Insuffisance cardiaque | Phase 3 | Traitement symptomatique | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, … | À vérifier |
| EvolocumabThe primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]). | Maladie coronarienne | Phase 4 | À vérifier | United States, Brazil, Sweden | À vérifier |
Essais cliniques
15| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Evolocumab | Maladie coronarienne | Phase 4 | NCT05284747 | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | ACTIVE_NOT_RECRUITING |
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Erenumab | Migraine | À vérifier | NCT05281770 | Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study | UNKNOWN |
| AMG334 | Migraine | Phase 4 | NCT03927144 | Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients | COMPLETED |
| Erenumab | Migraine | Phase 4 | NCT04265755 | INTERROGATE — Biomarker and Genetic Predictors of Erenumab Treatment Response | COMPLETED |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03832998 | OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | COMPLETED |
| Inebilizumab | Myasthénie | Phase 3 | NCT04524273 | MINT — Myasthenia Gravis Inebilizumab Trial | ACTIVE_NOT_RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04825678 | A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine | COMPLETED |
| Erenumab | Migraine | Phase 4 | NCT04084314 | APOLLON — Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study | COMPLETED |
| Erenumab | Migraine | À vérifier | NCT04628429 | CGRP-1 — CGRP Inhibition, Autonomic Function, and Migraine | RECRUITING |
| Inebilizumab | Myasthénie | Phase 2 | NCT06987539 | THYME — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) | RECRUITING |
| Inebilizumab | Lupus | Phase 2 | NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04252742 | EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | COMPLETED |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Erenumab | Advice to Health Care Providers: Achieving Successful Organ Donation. | The American journal of medicine | ||
| Erenumab | Consumption of Ultra-Processed Foods and Increased Risks of Prostate Cancer in a Random Sample of United States Adults. | The American journal of medicine | ||
| Erenumab Dose 2 | Neuro-Immune Axis in Trauma-Induced Heterotopic Ossification: Mechanisms and Therapeutic Implications. | Cells | ||
| Erenumab Dose 1 | Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial. | JAMA network open | ||
| Erenumab Dose 1 | Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study. | European journal of neurology | ||
| Erenumab Dose 1 | Effects of erenumab on migraine aura frequency: a REFORM study. | The journal of headache and pain | ||
| Inebilizumab | Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD. | Journal of neurology, neurosurgery, and psychiatry | ||
| Inebilizumab | Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases. | Frontiers in neurology | ||
| Inebilizumab | Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial. | JAMA neurology |